Literature DB >> 18463797

Lipid changes occuring in the course of hematological cancers.

Małgorzata Kuliszkiewicz-Janus1, Rafał Małecki, Abdulrahman Saeed Mohamed.   

Abstract

The relationship between plasma lipid levels and mortality from cardiovascular diseases has been shown in many studies, but there has been far less investigation into their relationship to non-cardiovascular diseases. The aim of this study was to investigate the lipid profile of individuals with hematological malignancies and its relationship to disease activity. 238 patients were included in the study: 84 with acute leukemia, 62 with non-Hodgkin lymphoma, 35 with Hodgkin's lymphoma, 32 with multiple myeloma, and 25 with myeloproliferative syndrome. The HDL cholesterol level of the patients differed to that of the individuals in the control group in the active disease period for all the analyzed disorders, but only remained statistically significant in the acute leukemia and non-Hodgkin lymphoma groups during the remission period. Smaller differences were observed for the remaining lipid fractions, except for the triglyceride level, which increased in the active disease period in all the analyzed disorders except non-Hodgkin lymphoma. The most pronounced changes in the lipid fractions occurred in the HDL cholesterol level, and were the most remarkable for acute leukemia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18463797      PMCID: PMC6275614          DOI: 10.2478/s11658-008-0014-9

Source DB:  PubMed          Journal:  Cell Mol Biol Lett        ISSN: 1425-8153            Impact factor:   5.787


  22 in total

1.  Return to normal values of lipid pattern after effective chemotherapy in acute lymphoblastic leukemia.

Authors:  D Scribano; S Baroni; L Pagano; C Zuppi; G Leone; B Giardina
Journal:  Haematologica       Date:  1996 Jul-Aug       Impact factor: 9.941

2.  Serum cholesterol levels and cancer mortality in 361,662 men screened for the Multiple Risk Factor Intervention Trial.

Authors:  R W Sherwin; D N Wentworth; J A Cutler; S B Hulley; L H Kuller; J Stamler
Journal:  JAMA       Date:  1987-02-20       Impact factor: 56.272

3.  Plasma kinetics of an artificial emulsion resembling chylomicrons in patients with chronic lymphocytic leukemia.

Authors:  A M Sakashita; S P Bydlowski; D A Chamone; R C Maranhão
Journal:  Ann Hematol       Date:  2000-12       Impact factor: 3.673

4.  Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects.

Authors:  A M Fiorenza; A Branchi; D Sommariva
Journal:  Int J Clin Lab Res       Date:  2000

5.  Prognostic relevance of lipoprotein cholesterol levels in acute lymphocytic and nonlymphocytic leukemia.

Authors:  S Baroni; D Scribano; C Zuppi; L Pagano; G Leone; B Giardina
Journal:  Acta Haematol       Date:  1996       Impact factor: 2.195

6.  Lipoprotein metabolism in patients with severe sepsis.

Authors:  Henk J van Leeuwen; Eric C J M Heezius; Geesje M Dallinga; Jos A G van Strijp; Jan Verhoef; Kok P M van Kessel
Journal:  Crit Care Med       Date:  2003-05       Impact factor: 7.598

7.  Total and HDL cholesterol in human hematologic neoplasms.

Authors:  S Dessì; B Batetta; D Pulisci; P Accogli; P Pani; G Broccia
Journal:  Int J Hematol       Date:  1991-12       Impact factor: 2.490

8.  Serum cholesterol level, body mass index, and the risk of colon cancer. The Framingham Study.

Authors:  B E Kreger; K M Anderson; A Schatzkin; G L Splansky
Journal:  Cancer       Date:  1992-09-01       Impact factor: 6.860

9.  Chemotherapy-associated changes in 31P MRS spectra of sera from patients with multiple myeloma.

Authors:  M Kuliszkiewicz-Janus; S Baczyński
Journal:  NMR Biomed       Date:  1995-05       Impact factor: 4.044

10.  [Lipid profile in hematologic neoplasms].

Authors:  Caterina Musolino; Luana Calabrò; Giacomo Bellomo; Maria Cincotta; Valeria Di Giacomo; Caterina Pezzano; Barbara Loteta; Vincenzo Rizzo; Salvatore Guglielmo; Andrea Alonci
Journal:  Recenti Prog Med       Date:  2002-05
View more
  17 in total

1.  Association between high-density lipoprotein cholesterol level and risk of hematologic malignancy.

Authors:  Su-Min Jeong; Taewoong Choi; Dahye Kim; Kyungdo Han; Seok Jin Kim; Sang Youl Rhee; Edward L Giovannucci; Dong Wook Shin
Journal:  Leukemia       Date:  2020-12-02       Impact factor: 11.528

2.  Low level of high-density lipoprotein cholesterol correlates with poor prognosis in extranodal natural killer/T cell lymphoma.

Authors:  Liang Wang; Pei-dong Chi; Hao Chen; Jin Xiang; Zhong-jun Xia; Yu-jing Zhang
Journal:  Tumour Biol       Date:  2014-03

3.  Rational Targeting of Cellular Cholesterol in Diffuse Large B-Cell Lymphoma (DLBCL) Enabled by Functional Lipoprotein Nanoparticles: A Therapeutic Strategy Dependent on Cell of Origin.

Authors:  Jonathan S Rink; Shuo Yang; Osman Cen; Tim Taxter; Kaylin M McMahon; Sol Misener; Amir Behdad; Richard Longnecker; Leo I Gordon; C Shad Thaxton
Journal:  Mol Pharm       Date:  2017-10-03       Impact factor: 4.939

4.  Serum cholesterol trajectories in the 10 years prior to lymphoma diagnosis.

Authors:  Sharon Hensley Alford; George Divine; Chun Chao; Laurel A Habel; Nalini Janakiraman; Yun Wang; Heather Spencer Feigelson; Delia Scholes; Doug Roblin; Mara M Epstein; Lawrence Engel; Suzanne Havstad; Karen Wells; Marianne Ulcickas Yood; Joan Fortuny; Christine Cole Johnson
Journal:  Cancer Causes Control       Date:  2017-11-30       Impact factor: 2.506

5.  Changes in the peripheral blood transcriptome associated with occupational benzene exposure identified by cross-comparison on two microarray platforms.

Authors:  Cliona M McHale; Luoping Zhang; Qing Lan; Guilan Li; Alan E Hubbard; Matthew S Forrest; Roel Vermeulen; Jinsong Chen; Min Shen; Stephen M Rappaport; Songnian Yin; Martyn T Smith; Nathaniel Rothman
Journal:  Genomics       Date:  2009-01-20       Impact factor: 5.736

6.  Exposure to statins and risk of common cancers: a series of nested case-control studies.

Authors:  Yana Vinogradova; Carol Coupland; Julia Hippisley-Cox
Journal:  BMC Cancer       Date:  2011-09-26       Impact factor: 4.430

7.  The PPARα agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism.

Authors:  Jianfeng Huang; Suman Kumar Das; Pooja Jha; Wael Al Zoughbi; Silvia Schauer; Thierry Claudel; Veronika Sexl; Paul Vesely; Ruth Birner-Gruenberger; Dagmar Kratky; Michael Trauner; Gerald Hoefler
Journal:  Biochim Biophys Acta       Date:  2013-04-26

8.  Statins use and the risk of all and subtype hematological malignancies: a meta-analysis of observational studies.

Authors:  Danitza Pradelli; Davide Soranna; Antonella Zambon; Alberico Catapano; Giuseppe Mancia; Carlo La Vecchia; Giovanni Corrao
Journal:  Cancer Med       Date:  2015-03-21       Impact factor: 4.452

9.  Metabolic abnormalities in pituitary adenoma patients: a novel therapeutic target and prognostic factor.

Authors:  Xin Zheng; Song Li; Wei-Hua Zhang; Hui Yang
Journal:  Diabetes Metab Syndr Obes       Date:  2015-08-05       Impact factor: 3.168

10.  The Relationship Between Hematological Malignancy and Lipid Profile.

Authors:  Erman Ozturk
Journal:  Medeni Med J       Date:  2021-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.